Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.
British journal of clinical pharmacology(2022)
摘要
These findings demonstrate selective targeting of monocytes in humans using the ESM approach and identify monocytopaenia as a novel outcome of ESM-HDACi treatment, with implications for potential benefit of these molecules in myeloid-driven diseases.
更多查看译文
关键词
ESM-HDAC391,histone deacetylase inhibitor,monocyte,monocytopaenia,myeloid,pharmacodynamics,pharmacokinetics
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要